产品介绍
Synonym
SOST, VBCH
Source
Recombinant Human Sclerostin /SOST Protein (rhSOST) Gln24-Tyr213 (Accession # AAI01087.1)was produced in human 293 cells (HEK293) at ACRObiosystems.
Molecular Characterization
rhSOST, fused with 6×his tag at the N-terminus, has a calculated MW of 22.5 kDa expressed. The predicted N-terminus is Gln24. Protein migrates as 28 kDa in reduced SDS-PAGE resulting from glycosylation.
Endotoxin
Less than 1.0 EU per μg of the rhSOST by the LAL method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.
Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC-8oC); After reconstitution under sterile conditions for 1 month (4oC-8oC) or 3 months (-20oC to -70oC).
SDS-PAGE
![SOST]()
The purity of rhSOST was determined by reduced SDS-PAGE and staining overnight with Coomassie Blue.
Background
Sclerostin (SOST) also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation).[1] It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease. [2-3]
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
References
- (1)Li X, et al., 2005, J. Biol. Chem. 280 (20): 19883–7.
- (2)Van Bezooijen RL, et al., 2007, J. Bone Miner. Res. 22 (1): 19–28.
- (3)Krause C, et al., 2010, J. Biol. Chem. 285 (53): 41614–26.
来宝会员